共 41 条
[1]
Blute ML(2004)The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus BJU Int 94 33-41
[2]
Leibovich BC(2016)CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition Am J Clin Oncol 39 98-106
[3]
Lohse CM(2018)Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma N Engl J Med 378 1277-1290
[4]
Buchbinder EI(2019)Sarcomatoid dedifferentiation in renal cell carcinoma: from novel molecular insights to new clinical opportunities Cancers (Basel) 12 99-86
[5]
Desai A(2022)Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma J Immunother Cancer 10 78-91
[6]
Motzer RJ(2021)Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma Clin Cancer Res 27 88-1034
[7]
Tannir NM(2020)Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab Int Cancer Conf J 9 1030-272
[8]
McDermott DF(2022)Immune checkpoint inhibitor combination therapy for renal cell carcinomas with concomitant inferior vena cava thrombi In Vivo 36 268-55
[9]
Debien V(2021)Preoperative ipilimumab/nivolumab combination therapy reduced operation risk by downstaging the inferior vena cava tumor thrombus extending to the right atrium in a metastatic renal cell carcinoma: a case report Urol Case Rep 40 66-592
[10]
Thouvenin J(2022)Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab IJU Case Rep 5 50-560